Fidaxomicin is a type of antibiotic medicine. It's used to treat a specific type of diarrhea caused by a bacteria called Clostridium difficile. It helps clear the infection from your digestive system.
Every report comes from a Lived member, sent anonymously.
Have you tried Dificid (Fidaxomicin) for Pseudomembranous Enterocolitis?
Fidaxomicin, sold under the brand name Dificid and also available as a generic tablet, is a prescription antibiotic used for one specific job: treating diarrhea caused by Clostridioides difficile, a bacterium usually called C. diff. C. diff infection most often follows a course of other antibiotics, which can disturb the normal gut bacteria and let C. diff multiply and release toxins that inflame the colon. Fidaxomicin is approved for adults and for children 6 months and older. The other main antibiotic for C. diff is oral vancomycin. In two large trials the two drugs cured the first bout of diarrhea about equally often, but people who took fidaxomicin were less likely to have the infection come back in the following weeks. About 7 in 10 fidaxomicin users stayed well through the month after treatment, compared with fewer than 6 in 10 vancomycin users. Because C. diff often returns, US infectious disease and gastroenterology experts now favor fidaxomicin as the first choice for a first episode that is not life-threatening, and it is also an option when the infection recurs. Its price has long limited its use, so vancomycin remains an accepted alternative when fidaxomicin is not covered or available.
Fidaxomicin belongs to the macrolide family of antibiotics, the same broad group as azithromycin and erythromycin, but it acts differently from them. It blocks the enzyme C. diff uses to read its own genes (RNA polymerase), so the bacteria cannot make the proteins they need and die off. Very little of the drug is absorbed into the bloodstream. Almost all of it stays in the intestine, which is exactly where the infection is, and leaves the body in the stool. It also targets a narrow range of bacteria, so it does less collateral damage to the healthy gut bacteria that help keep C. diff in check. That narrower effect is thought to be why the infection returns less often after fidaxomicin. The same features mean it cannot treat infections anywhere else in the body, such as pneumonia or a urinary tract infection.
Adults, and children who weigh at least 12.5 kg (about 28 pounds) and can swallow pills, usually take one 200 mg tablet twice a day, about 12 hours apart, for 10 days. It can be taken with or without food. Diarrhea often eases within the first few days, but the full course still matters: stopping early or skipping doses can leave the infection incompletely treated and encourage resistant bacteria. For a missed dose, take it when you remember unless the next dose is nearly due, and never double up. Younger or smaller children, and anyone who cannot swallow tablets, can use a liquid form dosed by weight. The pharmacy mixes it, it is kept in the refrigerator, each dose is measured with an oral syringe rather than a kitchen spoon, and any liquid left after 12 days is thrown away. For people with repeated recurrences, some specialists use a longer schedule that spreads doses out over several weeks. That differs from the standard label directions and is a decision for the treating clinician.
Most people tolerate fidaxomicin well. Nausea is the most common complaint, and vomiting or stomach pain also occur; in trials these happened about as often as with vancomycin. Children more often had fever, stomach pain, vomiting, diarrhea, constipation or a rash. Blood tests in trial patients occasionally showed anemia or a low count of neutrophils, the white blood cells that fight bacterial infection. Some trial patients had bleeding in the digestive tract, slightly more often than with vancomycin, although many were already seriously ill. Black or tarry stools, bright red blood in the stool, or vomit that contains blood or looks like coffee grounds should be reported to the care team right away. A rash or itching also warrants a prompt call. Serious allergic reactions are uncommon. Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing, needs emergency care: call 911.
Fidaxomicin should not be used by anyone who has had an allergic reaction to it or its ingredients. Some people who reacted to it had previously been allergic to other macrolide antibiotics, such as azithromycin, clarithromycin or erythromycin, so mention any antibiotic allergy before starting. Because so little enters the bloodstream, fidaxomicin has few meaningful drug interactions, and no dose change is recommended with other medicines. It is still worth giving the prescriber a full list of medicines, including any other antibiotics and acid-reducing drugs, since these can affect how C. diff is managed overall. There is too little information to know whether fidaxomicin poses a risk in pregnancy or passes into breast milk. Animal studies at much higher exposures showed no harm. Anyone pregnant or breastfeeding should weigh the need for treatment with the prescriber.
Most people start to feel better within the first few days, with fewer and firmer bowel movements. If diarrhea is not improving after a few days, or it worsens, with more belly pain, swelling or fever, contact the care team promptly, as this can signal a more severe infection that needs different treatment. Once the course is finished and symptoms have settled, a repeat stool test is not routinely needed. Testing is reserved for diarrhea that returns or persists. Recurrence is the main ongoing concern, most often within about 8 weeks. Fidaxomicin lowers that risk but does not remove it. Avoiding antibiotics that are not truly needed, and reminding every prescriber of a past C. diff infection, are the most useful steps afterward. For people who have had several recurrences, treatments that restore healthy gut bacteria may be offered.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Dificid (Fidaxomicin), what you've noticed, or ask the community a question.